Clinical trial · no report yet · Phase 3
DESTINY-B12
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
- NCT04739761 ↗
- Active not recruiting
- AstraZeneca
- 127 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 67 | |
| Podcasts | 35 | |
| X threads | 23 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab Deruxtecan
- Arms
- Trastuzumab Deruxtecan · Experimental
- Enrollment
- 506
- Primary outcomes
- Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)
- Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Jun 22, 2021
- Primary completion
- Feb 8, 2024
- Results posted
- Yes
- Registry record
- NCT04739761 · updated Aug 11, 2026
Publications
linked from the registry- Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gion M, Guarneri V, Bianchini G, Wildiers H, Escriva-de-Romani S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13. PubMed 39271844